Kiniksa Pharmaceuticals, Ltd. (KNSA)

Market Cap	1.86B
Revenue (ttm)	338.93M
Net Income (ttm)	-10.23M
Shares Out	71.08M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	409.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	392,861
Open	25.97
Previous Close	25.91
Day's Range	n/a
52-Week Range	14.12 - 27.88
Beta	0.38
Analysts	Strong Buy
Price Target	32.00 (+22.51%)
Earnings Date	Jul 23, 2024

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of gia...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 297
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA

Financial Performance

In 2023, KNSA's revenue was $270.26 million, an increase of 22.74% compared to the previous year's $220.18 million. Earnings were $14.08 million, a decrease of -92.32%.

Analyst Forecast

According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $32.0, which is an increase of 22.51% from the latest price.

Price Target

$32.0

(22.51% upside)

Analyst Consensus: Strong Buy